Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 46

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 46
---

June 30, 2025, Renovaro Cube had 14 full-time employees, and BioSymetrics had 6. As our growth plan and strategies develop, it must add
a significant number of additional managerial, operational, financial and other personnel. Future growth will impose significant added
responsibilities on members of management, including:

    ●
    identifying, recruiting, integrating, retaining and motivating additional employees;

    ●
    managing its internal development efforts effectively, including creating compliant programs and processes, and managing the regulatory requirements for its products, while complying with its contractual obligations to contractors and other third parties;

    ●
    expanding its operational, financial and management controls, reporting systems and procedures; and

    ●
    managing the increasing complexity associated with a larger organization and expanded operations.

Renovaro
Cube’s and BioSymetrics’ future financial performance and their ability to commercialize their respective products will depend,
in part, on their ability to effectively manage any future growth. Renovaro Cube’s and BioSymetrics’ management may also have
to divert a disproportionate amount of their attention away from day-to-day activities in order to manage these growth activities.
Renovaro Cube’s and BioSymetrics’ ability to successfully manage expected growth is uncertain given the fact that Renovaro
Cube has been in full operation as an independent company focusing on cancer diagnostics AI only since 2018, and BioSymetrics similarly
since 2017. Renovaro Cube’s and BioSymetrics’ executive management team’s lack of long-term experience working
together may adversely impact their ability to effectively manage its business and growth.

If Renovaro
Cube or BioSymetrics is not able to effectively expand its organization by hiring new employees, each may not be able to successfully
implement the tasks necessary to commercialize its products, which would have a negative impact on Renovaro Cube’s or BioSymetrics’
business and result of operations.

Renovaro
Cube’s or BioSymetrics’ employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements.

Renovaro
Cube and BioSymetrics are exposed to the risk of fraud, misconduct, or other illegal activity by its employees, independent contractors,
consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that
fails to comply with the rules and regulations of the Centers for Medicare & Medicaid